A5018857263- Dementia and Cognitive Impairment Research
- Health Systems, Economic Evaluations, Quality of Life
- Frailty in Older Adults
- Chronic Disease Management Strategies
- Alzheimer's disease research and treatments
- Cancer Immunotherapy and Biomarkers
- Geriatric Care and Nursing Homes
- Mental Health Treatment and Access
- Pharmaceutical Practices and Patient Outcomes
- Machine Learning in Healthcare
- Esophageal Cancer Research and Treatment
- Sleep and related disorders
- Parkinson's Disease Mechanisms and Treatments
- Patient-Provider Communication in Healthcare
- Economic and Financial Impacts of Cancer
- Healthcare Systems and Public Health
- Biosimilars and Bioanalytical Methods
- CAR-T cell therapy research
- COVID-19 and Mental Health
- Health Literacy and Information Accessibility
- Global Health Care Issues
- Health disparities and outcomes
- Medication Adherence and Compliance
- Healthcare Policy and Management
- Neurological Disorders and Treatments
McGill University
2007-2025
Eisai (United States)
2019-2025
Alzheimer’s Disease Neuroimaging Initiative
2023
Eisai (Japan)
2023
Bristol-Myers Squibb (Canada)
2016-2019
Laval Mayenne Technopole
2013
Merck Canada Inc. (Canada)
2012
Montreal General Hospital
2005-2007
Notre Dame of Dadiangas University
2006
Université de Montréal
2005
Abstract Purpose To control for protopathic bias, some studies have incorporated the concept of lag‐time into their exposure definition (time period before index date that was not considered in assessing exposure). The objective this study to introduce a procedure identify best be applied where bias is required. Methods We used data from case‐control carried out assess association between proton pump inhibitors (PPIs) and risk gastric cancer, using RAMQ databases. Exposure defined as number...
Alzheimer's disease (AD) is a progressive, neurodegenerative and the most common cause of dementia. Lecanemab humanized monoclonal antibody targeting amyloid protofibrils for treatment early AD. In phase II BAN2401-G000-201 trial (NCT01767311), lecanemab reduced accumulated in brain slowed progression on key global cognitive scales evaluating efficacy after 18 months treatment.A simulation model was used to predict long-term clinical outcomes patients with AD [i.e., mild impairment (MCI) due...
Background Lung cancer is the most common type of in world and associated with significant mortality. Nivolumab demonstrated statistically improvements progression-free survival (PFS) overall (OS) for patients advanced squamous non-small cell lung (NSCLC) who were previously treated. The cost-effectiveness nivolumab has not been assessed Canada. A contentious component projecting long-term cost outcomes relates to modeling approach adopted, two approaches being partitioned (PS) Markov...
Alzheimer's disease (AD), a progressive neurodegenerative disease, is the main cause of dementia and one leading causes death for elderly people in USA. Lecanemab humanized IgG1 monoclonal antibody targeting amyloid protofibrils treatment early AD [i.e., mild cognitive impairment (MCI) or dementia]. In recent 18-month phase III trial, using double-blind, placebo-controlled design, lecanemab led to reduced brain burden significant improvements functional abilities individuals with AD. An...
New immuno-oncology (I-O) therapies that harness the immune system to fight cancer call for a re-examination of traditional parametric techniques used model survival from clinical trial data. More flexible approaches are needed capture characteristic I-O pattern delayed treatment effects and, subset patients, plateau long-term survival. Using systematic approach data management and analysis, study assessed applicability as test case methods, investigated suitability restricted cubic splines...
Alzheimer’s disease (AD) is a progressive, neurodegenerative that affects memory, thinking, and behavior places substantial economic burden on caregivers healthcare systems. This early-phase study aimed to model lecanemab, humanized monoclonal antibody targeting amyloid protofibrils, for patients with early AD, estimate the potential value-based price (VBP) of lecanemab + standard care (SoC) compared SoC alone given an expected product profile informed by data from phase II trial payer...
Alzheimer's disease (AD) and mild cognitive impairment (MCI) have negative quality of life (QoL) economic impacts on patients their caregivers may increase along the continuum from MCI to mild, moderate, severe AD.
Alzheimer's disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data the large phase III CLARITY AD trial were used estimate societal value of lecanemab plus standard care (SoC) versus SoC alone against range willingness-to-pay (WTP) thresholds perspective in Japan.A simulation model was evaluate impact progression early based published...
To estimate Americans' willingness-to-pay (WTP) for universal access to a disease-modifying Alzheimer's disease (AD) treatment with discrete choice experiment in nationally representative sample. As part of this experiment, we examined whether providing information about the higher burden among minorities and persons lower socioeconomic status (SES) changes WTP. We conducted an using Understanding America Study (UAS) panel. Participants were provided general AD hypothetical that reduces...
Abstract Introduction We utilized the Veterans Affairs Healthcare System administrative database to study clinical decision-making processes for anti-amyloid therapy (AAT). Methods Patients with notes mentioning lecanemab were identified (March 2023–June 2024) manual review and structured queries. Results From an initial sample ( N = 2499), 1064 patients (55,000 notes) reviewed manually (mean age 76 years; 7.3% women; 9.2% Black; 3.9% Hispanic). The AAT group n 56) had lower rates of common...
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with memory, cognitive, and behavioral deficits, brings significant economic burden on caregivers healthcare systems. This study aims to estimate the long-term societal value of lecanemab plus standard care (SoC) versus SoC alone, corresponding range willingness-to-pay (WTP) thresholds based phase III CLARITY AD trial readouts from both US payer perspectives. An evidence-based model was developed simulate effects...
Early identification of individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD) is a clinical research imperative. Use diagnostic codes for MCI AD has limitations. We used notes to supplement in the Veterans Affairs Healthcare System (VAHS) electronic health records (EHR) identify establish cohorts recorded or AD. Targeted keyword searches ("Mild impairment;" "MCI") ("Alz*") were extract from VAHS EHR fiscal year (FY) 2010 through FY 2019. Iterative steps inclusion...
In Quebec, MED-ECHO database can be used to estimate inhospital length of stay (LOS) and number hospitalizations (NOH) both accurately reliably. However, access is time-consuming. Quebec medical claims (RAMQ) as an alternative source these measures. Considering the 'gold standard,' this study examined validity using RAMQ LOS NOH.We a cohort 3768 elderly patients with chronic obstructive pulmonary disease (COPD) between 1990 1996 identified those claims. Inhospital was defined total days...
US veterans have a unique dementia risk profile that may be evolving over time.Age-standardized incidence and prevalence of Alzheimer's disease (AD), AD related dementias (ADRD), mild cognitive impairment (MCI) was estimated from electronic health records (EHR) data for all aged 50 years older receiving Veterans Health Administration (VHA) care 2000 to 2019.The annual declined, as did ADRD incidence. increased 1.07% in 1.50% 2019, primarily due an increase the not otherwise specified. The...
Clinical Alzheimer's disease (AD) begins with mild cognitive impairment (MCI) and progresses to mild, moderate, or severe dementia, constituting a continuum that eventually leads death. This study aimed estimate the probabilities of transitions across those states. We developed mixed-effects multi-state Markov model transition probabilities, adjusted for 5 baseline covariates, using Health Retirement Study (HRS) database. HRS surveys older adults in United States bi-annually. Alzheimer...
New regimens for the treatment of chronic hepatitis C virus (HCV) genotype 3 have demonstrated substantial improvement in sustained virologic response (SVR) compared with existing therapies, but are considerably more expensive. The objective this study was to evaluate cost-effectiveness two novel all-oral, interferon-free patients HCV 3: daclatasvir plus sofosbuvir (DCV + SOF) and ribavirin (SOF RBV), from a Canadian health-system perspective.A decision analytic Markov model developed...
Abstract Background Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will be made. While identifying preferred therapeutic attributes new AD therapies necessary, few studies have explored how preferences may vary between the stakeholders. In this study, trade-offs among key amyloid plaque-lowering for were assessed using discrete choice experiment (DCE) and compared caregivers neurologists....